Pure Global AI
NCT06337266Completed

A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma

A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma After Radical Gastrectomy : A Multicenter Real-world Study
Fujian Medical UniversityClinicalTrials.gov
Verified
Study focus
Disease/Condition
Gastric Cancer
Study type
Observational
Sponsor & location
Primary sponsor
Fujian Medical University
Location
Fuzhou, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2023
End date
Mar 19, 2024
Enrollment
3622 participants
Primary outcome

5-year OS,5-year DFS

Summary

This study aimed to develop a novel Prognostic Oxidative Stress-Immune-Inflammatory Score
 (POSII Score) and introduce an innovative online calculator designed to predict long-term
 survival and assess the recurrence risk of gastric cancer (GC).

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06337266
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06337266 through Pure Global AI's free database. This phase not specified trial is sponsored by Fujian Medical University and is currently Completed. The study focuses on Gastric Cancer. Target enrollment is 3622 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.